Domestic cell therapy is in full swing, isolator is expected to usher in a market space of nearly 10 billion yuan

Cell therapy is to use the patient’s own or allogeneic adult cells or stem cells, processed by a series of bioengineering techniques such as acquisition, isolation, culture amplification, and screening, and then return them to the patient to repair tissues and organs.
Treatment methods
.
Due to the huge application potential of cell therapy in the treatment of cancer, autoimmune diseases, cardiovascular diseases and other major diseases, in recent years, not only foreign countries, but also domestic cell therapy research and development are in full swing.
With the continuous entry of capital, the entire cell therapy market continues to expand.

.
According to Frost & Sullivan's prediction, the market space for cell therapy in China will grow from 1.
3 billion yuan in 2021 to 58.
4 billion yuan in 2030, with an average annual growth rate of 53%
.
In the context of surging cell therapy, more and more cell therapy products will be promoted for commercial production in the future.
The industry generally believes that upstream equipment such as cell culture isolators will also usher in opportunities and increase costs in pharmaceutical companies.
Under the background of continuous upgrading of domestic equipment and policy support for the development of high-end equipment, the process of domestic substitution of upstream equipment is expected to be further accelerated
.
The domestic cell therapy isolator is expected to usher in a market space of nearly 10 billion yuan (Source: Pharmaceutical Network) What is a cell culture isolator? The cell culture isolator is an integrated centrifuge, carbon dioxide incubator and other cell culture-related functional components, which can complete cell culture-related operations in a closed aseptic environment, thereby meeting the requirements of cell product GMP production
.
As a flexible R&D and production platform for cell drugs, the cell culture isolator has the characteristics of high integration, customization, high R&D barriers, and high value
.
Some institutions believe that in the future, as more and more cell therapy products continue to advance backwards and the scale of commercial production continues to expand, the domestic isolator market is expected to reach a market size of nearly 10 billion
.
So, what is the current development status of the domestic cell culture isolator industry? It is understood that with the implementation of the new version of GMP, Chinese Pharmacopoeia and other relevant industry regulations, pharmaceutical companies have continuously improved their requirements for aseptic environment, and isolation technology has been widely used in China.
In recent years, isolators have been increasingly used by pharmaceutical companies.
focus on
.
CITIC Construction Investment previously analyzed in a research report that the leading overseas isolators include Skan, Getinge, Extract Technology, and Syntegon.
Among domestic isolator manufacturers, existing cell workstation manufacturers include Teflon, Tailin Biological, and Wenzhou Wei For Biotech, manufacturers with isolator technology include Chutian Technology and Morimatsu International
.
At present, although imported manufacturers still have advantages, some domestic isolator manufacturers are gradually emerging.
With the advantages of high cost-effective products, they are gradually favored by local pharmaceutical companies to help the production and quality control of cell therapy drugs
.
From the perspective of development trend, intelligence and modularization will be the development direction of the cell culture isolator industry, and it is also the path that the domestic isolator giants are taking
.
For example, in a survey conducted in September this year, Tailin Biotech stated that the company has core technologies such as isolator intelligent control and hydrogen peroxide flash vaporization.
It can carry out personalized and modular design according to customer needs, and combine cell therapy Multiple or even all processes are integrated to achieve closed or semi-closed aseptic operations, thereby meeting the requirements of different cell preparation processes
.
However, the company also pointed out that manufacturers that currently only have isolator technology must complete the development of these functional modules and operate stably, and need to undergo systematic verification.
This is an accumulation process that is technically difficult and takes a long time
.
Therefore, while seizing new opportunities, domestic isolator manufacturers also need to continuously increase R&D investment, work hard to solve technical problems, further reduce the operating costs of pharmaceutical companies, improve drug sterility protection capabilities, and escort the occupational health of personnel
.